Europe is losing the race for innovative drugs

In 2024, China and the USA led the introduction of new active substances in the pharmaceutical market, with Europe lagging behind. Factors contributing to China's success include competitive approaches, lower research costs, and a supportive government policy. Europe faces challenges due to high costs and a fragmented regulatory system, making it difficult to build a cohesive research ecosystem. Despite having strong academic institutions, Europe must increase investments in R&D and streamline procedures to compete effectively. The need for a unified innovation ecosystem is crucial for Europe to regain its position in the global pharmaceutical industry.